Valneva to showcase its potential Chikungunya vaccine and organize a panel discussion at the 23rd World Vaccine Congress in Washington D.C. | MarketSc

Valneva to showcase its potential Chikungunya vaccine and organize a panel discussion at the 23rd World Vaccine Congress in Washington D.C. | MarketSc

Valneva SE, a company that specializes in making vaccines, has shared that it will showcase its VLA1553, a vaccine candidate that fights chikungunya and needs only one shot. Moreover, the company will also lead a discussion about vaccines that deal with Zika at the 23rd World Vaccine Congress, occurring soon in Washington, D.C.

Valneva's Chief Medical Officer, Juan Carlos Jaramillo, MD, will be leading a roundtable discussion about the Zika vaccine. The event will take place on April 4, 2023, at 11.40am EDT. Valneva has already made progress in developing an inactivated whole-virus Zika vaccine candidate that completed Phase 1 before the COVID-19 pandemic. They are now considering the possibility of re-entering clinical development towards the end of this year or early next year, despite possible challenges.

Furthermore, a presentation will take place on April 5, 2023, at 9:40 am EST by Susanne Eder-Lingelbach, who is the Vice President of Clinical Development at Valneva. During this presentation, the clinical findings of Valneva's single-dose chikungunya vaccine candidate will be discussed. The vaccine is currently undergoing a regulatory process with the FDA. In the event that it is given approval, it would be the world's first vaccine that could help treat chikungunya, which is a medical requirement that has yet to be fulfilled.

During the conference, Juan Carlos Jaramillo and Thomas Lingelbach, Valneva's CEO, will be present to hold individual meetings. Those who are interested can send a request for a meeting to [email protected].

Valneva is going to present a scientific poster about the outcomes of their trial for a chikungunya vaccine candidate at the front entrance of the conference. They will also showcase their product at booth #503 within the exhibit area.

The VLA1553 is a potential vaccine against the chikungunya virus, which has been spreading rapidly across more than 100 countries. It is a type of live vaccine that only requires one dose, and it aims to reduce the strength of the virus by removing a section of its genetic makeup.

Valneva and Instituto Butantan from Brazil teamed up in January 2021 to make VLA1553 available to people in Low- and Middle-Income Countries (LMIC). They agreed to work together on the development, manufacturing, and marketing of VLA1553. This partnership is in line with the agreement signed by CEPI and Valneva in July 2019, which offers up to $24.6 million in funding with the backing of the European Union's Horizon 2020 program.

In March 2022, Valneva released the last set of information from the crucial Phase 3 study on VLA1553. They also shared the results of lot-to-lot consistency in May 2022. Lastly, they reported promising twelve-month persistence results in December 2022.

In 2018, VLA1553 was awarded the FDA Fast Track designation. Then in 2021, it received the Breakthrough Therapy designation and, in 2023, it was granted Priority Review. Moreover, the European Medicines Agency (EMA) recognized VLA1553 as a PRIority MEdicine (PRIME) in 2020.

Should it receive approval, the introduction of VLA1553 to its pre-existing array of vaccines would augment Valneva's commercial offerings. In doing so, Valneva aims to sell and market this vaccine by making use of its existing production and commercial channels.

Valneva is a company that specializes in creating vaccines that protect against infectious diseases where current medical treatments are lacking. They use a special approach to develop vaccines and apply their knowledge of vaccine science to make sure the vaccines work. Not only have they created three vaccines that are currently available, they are also quickly developing new vaccines to fight against diseases such as chikungunya and Lyme disease.

Phone: +33 (0)6 4516 7099 The provided information serves as an important reminder to ensure the accuracy of the phone number provided. It is crucial to provide a valid and reachable phone number for effective communication. In case of any changes in the number, kindly update it as soon as possible. Thank you. The details given are a vital prompt to make sure that the phone number given is correct. It is essential to provide a working and contactable number for efficient interaction. If any modifications are made to the number, please make sure to inform us promptly. Much obliged.

Valneva has made statements about their progress in research, development, and clinical trials concerning their prospective products, along with regulatory approval and product review. However, Valneva's actual results may not match their forward-looking statements. The statements use words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets,' or similar language. Valneva's expectations may be impacted by numerous factors, including vaccine development and manufacturing, clinical trial outcomes, regulatory action, competition, currency exchange, the global and European credit crisis, and patent protection. Early success may not predict later outcomes, so Valneva cannot guarantee that their statements will come true. Valneva disclaims responsibility for updating or changing their forward-looking statements.

Similar news
This week's most popular news